Grand Pharma Eye

Grand Pharma Eye (远大医药眼) is the ophthalmology-focused sub-brand of Grand Pharmaceutical Group Limited (远大医药集团有限公司, stock code 00512.HK), a科技创新型国际化医药企业 (innovation-driven international pharmaceutical enterprise) headquartered in Wuhan, Hubei, China. The parent group traces its history to 1939 and describes itself as combining nuclear medicine anti-tumor diagnostics and treatment technology, cardio-cerebrovascular precision interventional diagnostics and treatment technology, pharmaceutical technology, and biotechnology. Within this structure, the five-senses (五官科) business segment — which includes ophthalmology — is one of the group's core business areas, alongside cardio-cerebrovascular emergency care, respiratory and critical care, active pharmaceutical ingredients, mRNA platforms, nuclear medicine anti-tumor diagnostics and treatment, cardio-cerebrovascular precision intervention, and high-quality amino acids. The group's five-senses segment is operated through a set of member companies listed on the official website, including Hubei Grand Tiantianming Pharmaceutical Co., Ltd. (湖北远大天天明制药有限公司), Grand Beilin (Xi'an) Pharmaceutical Co., Ltd. (远大碑林（西安）药业有限公司), Grand Beilin (Chongqing) Pharmaceutical Co., Ltd. (远大碑林（重庆）药业有限公司), Tianjin Jingming New Technology Development Co., Ltd. (天津晶明新技术开发有限公司), Grand Beilin (Qinghai) Pharmaceutical Co., Ltd. (远大碑林（青海）药业有限公司), and Grand Pharma Huangshi Feiyun Pharmaceutical Co., Ltd. (远大医药黄石飞云制药有限公司). These entities collectively support the group's ophthalmology and five-senses product portfolio. Grand Pharmaceutical Group operates with more than 10,000 employees globally, over 30 domestic and overseas subsidiaries, 5 technology platforms, 8 R&D centers, and more than 200 products listed in China's medical insurance catalog. Its global R&D footprint includes centers in Wuhan Optics Valley (international R&D, high-end formulation technology, and cardio-cerebrovascular precision intervention devices), Boston (oncology intervention technology platform), Changzhou (cardio-cerebrovascular precision intervention devices), Australia (glycomics technology platform), Nanjing (mRNA technology platform), Shanghai (cardio-cerebrovascular precision intervention devices), and Chengdu (radiopharmaceutical R&D, RDC technology platform). As a sub-brand, Grand Pharma Eye represents the group's ophthalmology offerings within the broader five-senses segment. The group's stated corporate spirit is "敢为人先，共享成功" (Dare to be the first, share the success), and its operating philosophy is "提供好产品，修炼高境界" (Provide good products, cultivate a high realm). The group positions itself as a科技创新型国际化医药企业 committed to being respected by doctors and patients and giving back to society.

Grand Pharma Eye is the ophthalmology sub-brand of Grand Pharmaceutical Group Limited (远大医药集团有限公司), a Chinese pharmaceutical group whose history dates back to 1939. The parent group, headquartered in Wuhan, Hubei, has evolved into an innovation-driven international pharmaceutical enterprise with operations spanning nuclear medicine anti-tumor diagnostics and treatment, cardio-cerebrovascular precision interventional diagnostics and treatment, pharmaceutical technology, and biotechnology. The group's five-senses (五官科) segment, which encompasses ophthalmology, is one of its core business areas. According to the group's official website, the five-senses segment includes member companies such as Hubei Grand Tiantianming Pharmaceutical Co., Ltd. (湖北远大天天明制药有限公司), Grand Beilin (Xi'an) Pharmaceutical Co., Ltd. (远大碑林（西安）药业有限公司), Grand Beilin (Chongqing) Pharmaceutical Co., Ltd. (远大碑林（重庆）药业有限公司), Tianjin Jingming New Technology Development Co., Ltd. (天津晶明新技术开发有限公司), Grand Beilin (Qinghai) Pharmaceutical Co., Ltd. (远大碑林（青海）药业有限公司), and Grand Pharma Huangshi Feiyun Pharmaceutical Co., Ltd. (远大医药黄石飞云制药有限公司). These entities form the operational backbone of the group's ophthalmology and five-senses product portfolio. Grand Pharmaceutical Group is listed on the Hong Kong Stock Exchange under the ticker 00512.HK. The group reports more than 10,000 employees globally, over 30 domestic and overseas subsidiaries, 5 technology platforms, 8 R&D centers, and more than 200 products included in China's medical insurance catalog. Its global R&D network includes centers in Wuhan Optics Valley (international R&D and high-end formulation technology), Boston (oncology intervention technology platform), Changzhou (cardio-cerebrovascular precision intervention devices), Australia (glycomics technology platform), Wuhan Optics Valley (cardio-cerebrovascular precision intervention devices), Nanjing (mRNA technology platform), Shanghai (cardio-cerebrovascular precision intervention devices), and Chengdu (radiopharmaceutical R&D, RDC technology platform). The group has pursued a "Go Global" innovation strategy, in-licensing and partnering on innovative drugs and devices from the United States, Australia, Germany, Belgium, and other countries, and establishing deep collaborations with leading pharmaceutical companies, universities, and research institutions worldwide. Its corporate spirit is "敢为人先，共享成功" (Dare to be the first, share the success), and its operating philosophy is "提供好产品，修炼高境界" (Provide good products, cultivate a high realm). The group's vision is to be a pharmaceutical enterprise respected by doctors and patients and to give back to society.

• 1939

  Grand Pharmaceutical Group's history begins; the group traces its origins to this year.

Ophthalmology sub-brand within Grand Pharmaceutical Group's five-senses segment, backed by the group's innovation-driven international pharmaceutical platform.

1. 1首页 - 遠大醫藥集團grandpharma.cn
2. 2公司介绍 - 聚焦远大 - 遠大醫藥集團grandpharma.cn